To further investigate the role of HB-EGF–EGFR signaling in MM, we repeated the in vitro functional assays with pharmacological blocking of EGFR by erlotinib, which specifically inhibits the receptor’s tyrosine kinase. This evidence concerns the gene HBEGF and Miyoshi myopathy.